ecember 2025 – Conquest Research, LLC ("Conquest"), a portfolio company of Reynolda Equity Partners ("Reynolda"), has acquired NeuroTrials Research (“NeuroTrials”).

Headquartered in Winter Park, FL, Conquest is a clinical trial site network with expertise in neurology, orthopedics, rheumatology, pain, cardiometabolics, internal medicine, and other critical therapeutic areas. Conquest's Founder & CEO Mark Daley and CMO Dr. Anand Patel lead a team of experienced Principal Investigators serving global pharmaceutical companies, biotechs and CROs, with a track record of growth across multiple therapeutic indications.

Based in Atlanta, GA, NeuroTrials is a multi-specialty focused clinical research center that works with international pharmaceutical and device companies. NeuroTrials has developed clinical expertise across a range of select therapeutic areas with a particular emphasis on neurological diseases including Alzheimer’s Disease and sleep disorders including OSA, insomnia and narcolepsy. Founded in 1997 by Dr. Russell Rosenberg, NeuroTrials is currently led by two Principal Investigators, Dr. Michael Lacey and Dr. Matthews Gwynn, who will continue to guide the operation moving forward.

Conquest is building a strategic multi-state network of select sites in order to provide best-in-class service to its pharmaceutical customer base. The addition of NeuroTrials marks Conquest’s second addition and a strategic expansion into Atlanta and the surrounding region.

“We’re thrilled to welcome NeuroTrials into the Conquest Research family,” said Mark Daley. “This acquisition represents a significant milestone in our strategic continued expansion in the Southeast, aligning perfectly with our mission to advance clinical research in neurodegenerative disorders and in other diseases. NeuroTrials' experienced team, geographic presence, and shared therapeutic focus strengthen our ability to deliver exceptional services to our pharmaceutical partners and ultimately bring safer, more effective treatment options to the communities we serve.”

“Conquest continues to build on its strong momentum,” added Ken Clark, a Partner at Reynolda. “Mark and team are building a best-in-class site network by driving strong organic growth in Conquest’s core markets while continuing to expand into critical new geographies. The Reynolda team thinks highly of the business Dr. Lacey and his team have built and believe NeuroTrials is a natural fit with the Conquest platform. We look forward to supporting Management in growing the operation in Atlanta and beyond.”

Conquest continues to evaluate acquisition opportunities to add select sites with specific therapeutic expertise and geographic coverage to the expanding network. The Conquest team at Reynolda consists of Ken Clark, Bailey Burt and Blake Bahos.